 Live Conference Call and Webcast at 5:30 AM Pacific 8:30 AM Eastern PALO ALTO, Calif., March 16, 2022 PRNewswire -- Eiger BioPharmaceuticals, Inc. Nasdaq:EIGR, a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus HDV and other serious diseases, today announced that it will host a conference call on Thursday, March 17, 2022, at 5:30 AM Pacific 8:30 AM Eastern, to discuss the results from the Phase 3 TOGETHER study of Peginterferon Lambda for COVID-19. 